The conversation is about adding a low dose of pyrilutamide to a hair loss treatment regimen. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
The conversation discusses using minoxidil, finasteride, a dermastamp, and botanical oils like peppermint, rosemary, and pumpkin seed oil for hair growth. The user is considering using Alpha Infuse, which combines microneedling with plant oils, to enhance results.
The user is seeking alternatives to propylene glycol and glycerin for mixing with RU58841 due to allergies and greasiness. Suggestions include reducing glycerin and considering stemoxydine as a solvent.
PP405 is progressing to Phase 2b trials, with results expected in late 2025 or early 2026, and potential Phase 3 trials in 2026. Some users experienced side effects from finasteride and are hopeful for PP405 as an alternative treatment.
GentleIris stopped hormone-induced hair loss with diet changes but couldn't regrow lost hair. A reply suggested microneedling instead of Platelet-Rich Plasma Therapy (PRP) for hair regrowth.
The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.
The user has been using finasteride, minoxidil, and microneedling consistently for one month to improve hair regrowth. They also use collagen peptides, pumpkin seed oil, vitamin D, biotin, nizoral shampoo, adenosine shampoo, caffeine topical, and rosemary oil as part of their routine.
GT20029 is a potential treatment for androgenetic alopecia, addressing the root cause by targeting androgen receptors, unlike Minoxidil or Finasteride. It is seen as a preventative measure rather than a regrowth agent, with hopes for market release soon.
RU58841 was used by some for hair loss, but concerns about side effects like gynecomastia and safety were raised. Alternatives like finasteride, minoxidil, pyrilutamide, and alfatradiol were discussed, with some users reporting better experiences with these treatments.
The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.
A 21-year-old female shared her 4-month hair growth progress using Minoxidil 5%, finasteride 1mg, Theradome LLLT, Viviscal vitamins, and PRP treatments twice. Commenters praised her progress and discussed other treatments like microneedling, but she noted her dermatologist advised against it due to potential scalp damage.
A user is seeking advice on using a spray containing 0.3% finasteride and 6% minoxidil for hair loss. Another user suggests applying it in the morning to avoid transferring it to pillows and recommends reading a guide for microneedling advice.
A 46-year-old male shared his 3-week progress using HIMS serum with Finasteride 0.3% and Minoxidil 6%, showing improvement without noticeable shedding. His routine includes vitamins, a healthy diet, and specific hair care practices like microneedling and using caffeine solution.
SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.
The user has been using a hair solution with 0.3% finasteride and 5% minoxidil, along with microneedling, but is experiencing more thinning on one side. Suggestions include checking application techniques and ensuring microneedling is not overdone.
The discussion is about using ASCEplus HRLB exosomes for hair loss treatment, which combines 10 billion exosomes with growth factors, nutrients, biotin, and copper tripeptide. The treatment is expensive and typically administered via scalp injections, but in Europe, it's done with microneedling.
The conversation discusses using 23andme to determine if someone might respond well to minoxidil for hair loss treatment, and mentions the user's personal experience with micro-needling and minoxidil.
PP405 is a potential hair loss treatment showing promising early results, with hopes for market release by 2028, but skepticism remains due to inconclusive data and past disappointments with similar products. Current treatments like Minoxidil and Finasteride have side effects, leading some to anticipate PP405 as a safer alternative, though its effectiveness compared to placebo is debated.
The user is experiencing hair regrowth using 1mg oral finasteride daily, Minoxidil foam twice a day, and microneedling weekly with a 1.5mm needle. They are seeking feedback and suggestions to optimize their hair regrowth.
The user Consistent-Gene1334 shared their positive results in regrowing hair by using topical minoxidil and oral finasteride. Other users in the conversation praised the results and discussed the effectiveness of these treatments for diffuse thinning.
The user experienced significant hair regrowth after starting oral minoxidil (2.5mg) and dutasteride (0.5mg) daily, and is considering resuming microneedling at home with a dermapen. They are concerned about potential risks of microneedling, such as scarring, and are seeking advice on needle length and frequency.
The user experienced side effects from a hair loss treatment and is considering using pyrilutamide, alfatradiol, and possibly minoxidil. They are unsure about starting minoxidil immediately or waiting to see the effects of the other treatments.
The user experienced severe hair shedding despite using oral finasteride, minoxidil, dutasteride, and RU58841, and was diagnosed with Non-Alcoholic Fatty Liver Disease (NAFLD). They are considering switching to topical treatments due to the ineffectiveness of their current regimen.
Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. HMI 115 shows anecdotal success in Phase I trial, users seek group buy for research chemical.
The conversation discusses the potential benefits of adding Vitamin B6 (P-5-P) to topical hair loss treatments like RU58841, finasteride, or minoxidil. The user suggests that Vitamin B6 might enhance these treatments by naturally lowering scalp prolactin.
ET-02 showed significant hair growth in five weeks, outperforming minoxidil, with a non-hormonal mechanism that avoids side effects of treatments like finasteride. A phase 2 trial is planned to further assess ET-02's efficacy and safety.
The conversation discusses HMI 115, a new hair loss treatment with promising results, showing a significant increase in hair density after two months. Some users are skeptical, while others are hopeful for its release and potential affordability.